This article is part of the supplement: Advances in systemic sclerosis and related fibrotic and vascular conditions
Genetic factors in systemic sclerosis
1 Division of Rheumatology and Clinical Immunogenetics, University of Texas, Houston Health Science Center, Fannin, Houston, Texas 77030, USA
2 Division of Rheumatology, Medical University of South Carolina, Jonathan Lucas Street, Charleston, South Carolina 29425, USA
Arthritis Research & Therapy 2007, 9(Suppl 2):S5 doi:10.1186/ar2189Published: 15 August 2007
A number of genetic loci have been identified that appear to be associated with systemic sclerosis (SSc; scleroderma). There is mounting evidence suggesting that these genetic associations may in fact be associated with distinct phenotypes in SSc based on autoantibody pattern rather than with SSc as a single disease entity. This may ultimately have implications for approaches to therapy as well as responses to therapy. The most promising candidate genes are those involved in pathways that lead to the vascular damage and fibrosis that are the hallmarks of this disease. There is uncertainty, however, regarding the nature of the key pathological mechanisms that link these two disease processes. Recent studies have focused on Fli1 (friend leukaemia integration 1), a transcription factor that is found in immune cells, fibroblasts, and endothelial cells that regulates collagen gene function and angiogenesis. Fli1 is dysregulated in SSc skin and dermal blood vessels, and appears to play a pathological role in SSc skin fibrosis and vessel degeneration. Whether this dysregulation is due to genetic polymorphisms in the Fli1 pathway or to epigenetic mechanisms is not clear.